Understanding the neural mechanisms of Lisdexamfetamine dimesylate (LDX) pharmacotherapy in binge-eating disorder.
Phase of Trial: Phase IV
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Binge-eating disorder
- Focus Pharmacodynamics
- 01 Jun 2018 Status changed from not yet recruiting to recruiting.
- 10 May 2018 Planned initiation date changed from 30 Apr 2018 to 14 May 2018.
- 25 Apr 2018 New trial record